Early initiation of statin therapy in acute coronary syndromes: A review of the evidence

Journal of Interventional Cardiology

Volumn 18, Issue 1, 2005, Pages 55-63

  Rondina, Matthew T ^a   Muhlestein, Joseph B ^b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b LDS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; C REACTIVE PROTEIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN; SIMVASTATIN;

ACUTE HEART INFARCTION; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; FEMALE; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; MYOPATHY; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; SURVIVAL RATE; TREATMENT INDICATION; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

CORONARY DISEASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PROSPECTIVE STUDIES; SYNDROME;

EID: 16344394820     PISSN: 08964327     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1540-8183.2005.04103.x     Document Type: Review

References (45)

1. Group SSSS. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
2. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: The Cholesterol and Recurrent Events (CARE) Trial investigators. N Eng J Med 1996;335:1001-1009.
3. Group LS. Prevention of cardiovascular events and deaths with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels: The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. N Eng J Med 1998;339:1349-1357.
4. Waters DD, Hsue PY. What is the role of intensive cholesterol lowering in the treatment of acute coronary syndromes. Am J Cardiol 2001;88:7-16.
5. Sposito AC, Chapman MJ. Statin therapy in acute coronary syndromes: Mechanistic insight into clinical benefit. Arterioscler Thromb Vasc Biol 2002;22:1524-1534.
6. Correia LC, Sposito AC, Passos LC, et al. Short-term effect of atorvastatin (80 mg) on plasma lipids of patients with unstable angina pectoris or non-Q-wave myocardial infarction. Am J Cardiol 2002;90:162-164.
7. Davignon J, Laaksonen R. Low-density lipoprotein-independent effects of statins. Curr Opin Lipidol 1999;10:543-559.
8. Li JJ, Chen XJ. Simvastatin inhibits interleukin-6 release in human monocytes stimulated by C-reactive protein and lipopolysaccharide. Coron Artery Dis 2003;14:329-334.
9. Ridker P, Rifai N, Pfeffer MA, et al, for the Cholesterol and Recurrent Events (CARE) investigators. Long-term effects of pravastatin on plasma concentrations of C-reactive protein. Circulation 1999;100:230-235.
10. Kinlay S, Rifai N, Libby P, et al. Effect of atorvastatin on C-reactive protein in patients with acute coronary syndromes: A substudy of the MIRACL trial. J Am Coll Cardiol 2000;39:304A.
11. Plenge JK, Hernandez TL, Weil KM, et al. Simvastatin lowers C-reactive protein within 14 days: An effect independent of low-density lipoprotein cholesterol reduction. Circulation 2002;106:1447-1452.
12. Falk E. Why do plaques rupture? Circulation 1992;86(suppl. III):30-42.
13. Ridker P, Rifai N, Pfeffer MA. Inflammation, pravastatin and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 1998;98:839-844.
14. Williams JK, Sukhova GK, Herrington DM, et al. Pravastatin has cholesterol lowering independent effects on the artery wall of atherosclerotic monkeys. J Am Coll Cardiol 1998;31:684-691.
15. Aikawa M, Voglic SJ, Sugiyama S, et al. Dietary lipid lowering reduces tissue factor expression in rabbit atheroma. Circulation 1999;100:1215-1222.
16. Aikawa M, Rabkin E, Sugiyama S, et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation 2001;103:276-283.
17. Bustos C, Hernandez-Presa MA, Ortega M, et al. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol 1998;32:2057-2064.
18. Aikawa M, Rabkin E, Voglic SJ, et al. Lipid lowering promotes accumulation of mature smooth muscle cells expressing smooth muscle myosin heavy chain isoforms in rabbit atheroma. Circ Res 1998;83:1015-1026.
19. Aikawa M, Rabkin E, Okada Y, et al. Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: A potential mechanism of lesion stabilization. Circulation 1998;97:2433-2444.
20. Crisby M, Nordin-Fredriksson G, Shah PK, et al. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: Implications for plaque stabilization. Circulation 2001;103:926-933.
21. Falk E. Unstable angina with fatal outcome: Dynamic coronary thrombosis leading to infarction and/or sudden cardiac death: autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion. Circulation 1985;71:699-708.
22. Hangartner JR, Charleston AJ, Davies MJ, et al. Morphological characteristics of clinically significant coronary artery stenosis in stable angina. Br Heart J 1986;56:501-508.
23. Davies MJ, Thomas A. Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death. N Eng J Med 1984;310:1137-1140.
24. Marmur JD, Thiruvikraman SV, Fyfe BS, et al. Identification of active tissue factor in human coronary atheroma. Circulation 1996;94:1226-1232.
25. Ardissino D, Merlini PA, Ariens R, et al. Tissue-factor antigen and activity in human coronary atherosclerotic plaques. Lancet 1997;349:769-771.
26. Dupuis J, Tardiff JC, Cernacek P, et al. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes: The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. Circulation 1999;99:3227-3233.
27. Stenestrand U, Wallentin L. Early statin treatment following acute myocardial infarction and 1-year survival. JAMA 2001;285:430-436.
28. Aronow HD, Topol EJ, Roe MT, et al. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: An observational study. Lancet 2001;357:1063-1068.
29. Heeschen C, Hamm CW, Laufs U, et al. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation 2002;105:1446-1452.
30. Walter DH, Fichtlscherer S, Britten MB, et al. Benefits of immediate initiation of statin therapy following successful coronary stent implantation in patients with stable and unstable angina pectoris and Q-wave acute myocardial infarction. Am J Cardiol 2002;89:1-6.
31. Newby LK, Kristinsson A, Bhapkar MV, et al. Early statin initiation and outcomes in patients with acute coronary syndromes. JAMA 2002;287:3087-3095.
32. Michels KB, Braunwald E. Estimating treatment effects from observational data: Dissonant and resonant notes from the SYMPHONY trials. JAMA 2002;287:3130-3132.
33. Arntz HR, Wunderlich W, Schnitzer L. The decisive importance of cholesterol lowering therapy for coronary lesions and clinical course immediately after and acute coronary event: Short and long-term results of a controlled study. Circulation 1998;98(suppl. 1):1-45.
34. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: A randomized controlled trial. JAMA 2001;285:1711-1718.
35. Aronow HD. The Myocardial Ischemia Reduction with Acute Cholesterol Lowering trial: MIRACuLous or not, it's time to change current practice. Curr Control Trials Cardiovasc Med 2002;3:3.
36. Van Boven AJ, Liem A, Veeger NJ, et al. Fluvastatin on risk diminishing after acute myocardial infarction. 73rd Scientific Sessions of the American Heart Association, New Orleans, LA, November 2000. Clin Cardiol 2001;24:85-88.
37. Cannon CP, McCabe CH, Belder R, et al. Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT)-TIMI 22 trial. Am J Cardiol 2002;89:860-861.
38. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Eng J Med 2004;350:1495-1504.
39. Blazing MA, De Lemos JA, Dyke CK, et al. The A-to-Z Trial: Methods and rationale for a single trial investigating combined use of low-molecular-weight heparin with the glycoprotein IIb/IIIa inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy. Am Heart J 2001;142:211-217.
40. de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: Phase Z of the A to Z trial. JAMA 2004;292:1307-1316.
41. Nissen SE. High-dose statins in acute coronary syndromes: Not just lipid levels. JAMA 2004;292:1365-1367.
42. Muhlestein JB, Horne BD, Bair TL, et al. Usefulness of in-hospital prescription of statin agents after angiographic diagnosis of coronary artery disease in improving continued compliance and reduced mortality. Am J Cardiol 2001;87:257-261.
43. Hamm CW, Bertrand M, Braunwald E. Acute coronary syndrome without ST elevation: Implementation of new guidelines. Lancet 2001;358:1533-1538.
44. Cannon C. Improving acute coronary syndrome care: The ACC/AHA guidelines and critical pathways. J Invasive Cardiol 2003;15(Suppl. B):22-27.
45. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 2004;44:720-732.